Form 4: Tyra Biosciences CDO Sells 8,000 Shares

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on February 12, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Bensen, Chief Discovery Officer of Tyra Biosciences, Inc. (TYRA), sold a total of 8,000 shares of common stock.
• The sales occurred on February 12, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024.
• One block of 2,128 shares was sold at a weighted average price of $31.5018 per share, with actual sale prices ranging from $31.02 to $31.75.
• Another block of 5,872 shares was sold at a weighted average price of $33.3666 per share, with actual sale prices ranging from $32.98 to $33.85.
• Following these transactions, Daniel Bensen beneficially owns 146,981 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-arranged 10b5-1 plan, which typically indicates planned liquidity or diversification rather than a reaction to new, negative information.

Negatives

• The Chief Discovery Officer reduced his direct ownership in the company by 8,000 shares.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales, particularly by key executives like a Chief Discovery Officer, are routinely monitored by investors for insights into management's confidence. However, sales executed under a Rule 10b5-1 plan, as in this case, are pre-scheduled and generally considered less indicative of immediate sentiment compared to open-market, discretionary sales.

Related Party Transactions

• The sale of common stock by a Chief Discovery Officer is a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The reduction in direct ownership by a key executive might be viewed with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The transaction is an insider sale under a pre-arranged 10b5-1 plan, which is a routine event for executives managing their personal portfolios. It does not provide new fundamental information about the company's operational performance or future prospects that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on the company's underlying fundamentals rather than this specific insider transaction.

Keywords

Tyra Biosciences, TYRA, Insider Trading, Form 4, Daniel Bensen, Stock Sale, 10b5-1 Plan, Chief Discovery Officer, Biotechnology